ValuEngine upgraded shares of VIVUS (NASDAQ:VVUS) from a sell rating to a hold rating in a research report released on Thursday, ValuEngine reports.
NASDAQ:VVUS opened at $3.26 on Thursday. The stock’s 50-day simple moving average is $3.49. VIVUS has a 52 week low of $2.15 and a 52 week high of $7.10.
Large investors have recently added to or reduced their stakes in the company. Sterling Investment Advisors Ltd. bought a new position in shares of VIVUS during the 1st quarter worth about $42,000. Alambic Investment Management L.P. bought a new position in shares of VIVUS during the 1st quarter worth about $51,000. Finally, Spark Investment Management LLC bought a new position in shares of VIVUS during the 1st quarter worth about $98,000. 15.60% of the stock is owned by institutional investors.
VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.
Featured Article: What is a balanced fund?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.